News + perspectives
Company updates, scientific perspectives, publications, and milestones from KiraGen Bio.
Latest updates
KiraGen's Head of Immunoinformatics contributed to three recent studies spanning tumor biology, single-cell analysis, and the reliability of biomedical machine learning.
Read updateCo-founder and CEO Aaron Edwards will present KiraGen's approach to multiplex engineering for durable CAR-T activity in glioblastoma on September 15 at the CAR-TCR Summit in Boston.
Read updateThe former Poseida cell-therapy CSO brings experience in allogeneic CAR-T engineering, platform development, and clinical translation to KiraGen's scientific advisory team.
Read updateKiraGen moved into Tufts Launchpad | BioLabs in downtown Boston, expanding its access to flexible laboratory infrastructure, shared resources, and a collaborative biotech community.
Read updateCo-founder and CEO Aaron Edwards presented KiraGen's approach to building allogeneic CAR-T cells with intrinsic resistance to multiple suppressive pathways during an invited ASGCT symposium.
Read updateAdditional provisional filings related to engineered immune cells expand KiraGen's developing intellectual property portfolio around its platform and product programs.
Read updateAn Incite Labs-supported collaboration will evaluate KiraGen's multiplex-engineered CAR-T approach in dedifferentiated liposarcoma models.
Read updateThe venture philanthropy grant supports evaluation of KiraGen's engineered CAR-T candidates in patient-derived GBM tumoroids to help guide continued product development.
Read updateKiraGen highlighted co-founder and CSO Ryan Murray's research on coordinated engineering against rejection and overlapping tumor suppression.
Read updateThe foundation joined KiraGen as an investor in support of durable cell-therapy approaches for brain cancers.
Read updateThe translational research grant supports development of suppression-resistant CAR-T cells for DIPG and diffuse midline glioma, extending KiraGen's approach into pediatric brain tumors.
Read updateThe award provides a $50,000 credit toward LabCentral laboratory space and a one-year fellowship, expanding KiraGen's access to infrastructure, support, and Boston's biotech community.
Read updateThe award expands KiraGen's access to high-dimensional protein profiling, enabling deeper measurement of how engineered CAR-T cells respond to suppressive tumor signals.
Read updateThe Penn neurosurgeon and glioblastoma CAR-T investigator brings clinical, translational, and CNS-delivery expertise to guide KiraGen's brain tumor program.
Read updateLabCentral and C10 Labs selected KiraGen for a cohort combining wet-lab infrastructure, computation, and company-building support.
Read updateWe’re proud to share that our CEO & Co-Founder, Aaron Edwards, was recently interviewed on The Sheekey Science Show, a leading science communication platform hosted by Eleanor Sheekey. In this in-depth conversation, Aaron shares…
Read updateCo-founder and CSO Ryan Murray presented preclinical findings from KiraGen's five-edit CAR-T precursor during a GenScript exhibitor showcase at ASGCT 2025.
Read updateKiraGen was selected as one of ten companies from more than 200 applicants for Recode's healthcare AI program.
Read updateKiraGen was selected as a Boston Regional Finalist in the Harvard Business School New Venture Competition's Alumni Track.
Read updateAn exploratory subcutaneous GBM mouse study provided early in vivo evidence supporting KiraGen's thesis that CAR-T cells may need protection from several suppressive pathways at once.
Read updateThe collaboration brings Flash BioSolutions' LentiCare vector platform into proof-of-concept and subsequent CAR-T development work.
Read updateWe are thrilled to announce that our co-founder and CEO, Aaron Edwards, was recently featured as a special guest on the esteemed "Beyond the Square" podcast, hosted by William Wang. In this illuminating episode, Aaron delves into…
Read updateWe are excited to announce a significant milestone for KiraGen Bio and our mission towards inclusive innovation: Aaron Edwards, our Co-Founder and CEO, has been selected as a 2024 Termeer Fellow. This achievement is not only a…
Read updateWe are thrilled to announce KiraGen Bio's participation in the prestigious Harvard New Venture Competition, a testament to our dedication to pioneering advancements in CAR-T cell therapies for solid tumors. Amidst a competitive…
Read updateKiraGen has been selected as a finalist in the 13th @UMassM2D2 2024 #200KChallenge! Join us IN-PERSON in Lowell at the Finalist Pitch-Off on March 27. Details and FREE registration:…
Read updateWe're excited to share a pivotal update from KiraGen Bio: our move to the Harvard Pagliuca Harvard Life Lab. This transition is a significant stride in our quest to revolutionize CAR-T cell therapies for solid tumors, positioning…
Read updateKiraGen Bio has been selected as finalists for the 2024 Cohort of Nucleate's Activator Program, specifically within the Boston region, amongst 18 distinguished teams. This selection highlights KiraGen's role in pioneering CAR-T…
Read updateWe're proud to announce that Aaron Edwards, Co-Founder of KiraGen Bio, has recently published a compelling blog post for Harvard Business School, detailing his summer internship experience at Eli Lilly. The post offers an…
Read updateKiraGen is honored to announce our latest achievement – taking home the top prize at the Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Business, and the Environment Ventures Competition. This accolade is a…
Read updateNavigating the vibrant and diverse ecosystem of the Harvard Business School Shark Tank competition, KiraGen Bio is proud to have secured a place in the semi-finals, distinguishing ourselves in a field often dominated by sectors…
Read updateRyan Murray, the visionary Co-Founder and Chief Scientific Officer of KiraGen Bio, has been selected to join the esteemed third cohort of the Fifty 50 program, hosted by the tech bio VC firm Fifty Years. This exclusive initiative…
Read updateFor patients and families
KGEN-001 is a research-stage program. It is not in clinical trials and is not available to patients today.
KiraGen will share trial information if and when a study begins.
If you or someone you love is living with glioblastoma, the National Brain Tumor Society Clinical Trial Finder and ClinicalTrials.gov provide information about enrolling studies.
